$NERV News
Last published 1w ago
- 1w agoNERVMinerva Neurosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoNERVMinerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic
- 1w agoNERVMinerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article...
- 2w agoNERVMinerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireBURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 2w agoNERVMinerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of SchizophreniaGlobeNewswireBURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 2mo agoNERVMinerva Neurosciences to Participate in Two Upcoming Investor ConferencesGlobeNewswireBURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3mo agoNERVMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the
- 5mo agoNERVMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsGlobeNewswireBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 5mo agoNERVMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 6mo agoNERVMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesGlobeNewswireConfirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction
- 7mo agoNERVMinerva Announces Leadership TransitionGlobeNewswireBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 7mo agoNERVMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaGlobeNewswireRoluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON,
- 7mo agoNERVMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026GlobeNewswireTrial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the
- 8mo agoNERVSTIFEL 2026 VIRTUAL CNS FORUM - MINERVA NEUROSCIENCES INCEarnings Call TranscriptsGreat, thanks very much. It's my pleasure to be introducing Nerva Neuroscience's team. Remy, it's always good to see you. Thanks for joining. I appreciate it. Maybe I'll have you give a 10-minute overview of the company
- 8mo agoNERVMinerva Neurosciences to Participate in The Citizens Life Sciences ConferenceGlobeNewswireBURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 9mo agoNERVMinerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026GlobeNewswireBURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 11mo agoNERVMinerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of DirectorsGlobeNewswireBURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 1y agoNERVMinerva Neurosciences Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 1y agoNERVMinerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if ApprovedGlobeNewswireMinerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone's clinical development and
- 1y agoNERVMinerva Neurosciences Provides Business Updates and Second Quarter Financial ResultsGlobeNewswireFDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) --
- 1y agoNERVMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 1y agoNERVMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 2y agoNERVMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 2y agoNERVMinerva Neurosciences Reports Second Quarter 2024 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 2y agoNERVMinerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 2y agoNERVMinerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaGlobeNewswireBURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 2y agoNERVMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketGlobeNewswireBURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoNERVMinerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewswireFDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024 BURLINGTON,
- 3y agoNERVMinerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023GlobeNewswireBURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 3y agoNERVAmyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange - NCT05837507ClinicalTrials.govDifference in change in functional abilities between the experimental and control groups over 6 months of follow-up., Difference in change in functional abilities between the experimental and control groups during 3 months of follow-up (Between 3 months and 6 months)., Difference in change in functional abilities between the experimental and control groups during 3 months of follow-up (Between Bas ...
- 3y agoNERVMinerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business UpdatesGlobeNewswireBURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
- 3y agoNERVMinerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023GlobeNewswireBURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 3y agoNERVMinerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewswireBURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 4y agoATAICYBNNERVSAGEGreater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug CandidatesPR NewswirePALM BEACH, FL, Nov. 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to relieve anxiety and tension, work
- 4y agoNERVMinerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesGlobeNewswireBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 4y agoNERVMinerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022GlobeNewswireBURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 4y agoNERVMinerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewswireBURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
- 4y agoNERVMinerva Neurosciences Announces Listing Transfer to Nasdaq Capital MarketGlobeNewswireBURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported a listin
- 4y agoNERVMinerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaGlobeNewswireWALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the co
- 4y agoNERVUnderstanding Effects of Folic Acid on the Methylosome and Transcriptome of Women With Spina Bifida Affected Pregnancies - NCT05500690ClinicalTrials.govChanges in DNA Methylation patterns, Changes in serum folate concentration
- 4y agoNERVMinerva Neurosciences Reports Second Quarter 2022 Financial Results and Business UpdatesGlobeNewswireWALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business
- 4y agoNERVRegistry for Evaluation of Lumbar Arthrodesis Sagittal alignmEnt - NCT05448092ClinicalTrials.govImproved Clinical Status, Adverse events, Presence of post-operative complications, Occurrence of Junctional post-operative pathology
- 4y agoNERVMinerva Neurosciences Reports First Quarter 2022 Financial Results and Business UpdatesGlobeNewswireWALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business
- 4y agoNERVMinerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewswireWALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS) disorders, announced today that it has received the offi
- 4y agoNERVImplementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis - NCT05277740ClinicalTrials.govChange from Baseline in Symbol Digit Modalities Test (SDMT) score at Month 12, Change from Baseline in the Expanded Disability Status Scale (EDSS) score at Month 12, Change from Baseline in the Brief International Cognitive Assessment for MS (BICAMS) scores at Month 12, Change from Baseline in the Multiple sclerosis functional composite (MSFC) scores at Month 12